Effect of Tranexamic Acid in Upper Gastrointestinal Bleeding

• Status: Withdrawn
• Trial end date: 2011-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators hypothesize that addition of Tranexamic acid, an antifibrinolytic agent, to conventional therapy will lead to an improved outcome characterized by lower transfusion requirements.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Oklahoma
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• All patients with GI bleed if the following criteria are met:

• has received 4 units of PRBCs within a 24-hour period, or

• has orthostatic hypotension (drop in SBP of 20mmHg or drop in DBP of 10mmHg after fluid resuscitation with at least 20ml/Kg of either isotonic fluid and/or PRBCs), or

• if the MAP remains below 60mmHg after fluid resuscitation, and

• written informed consent is obtained from the subject or legally authorized representative.

Exclusion Criteria:

• Pregnant or lactating women

• Known to have gastrointestinal malignancy

• On anticoagulation therapy

• Patients with history of thromboembolism

• Patients with history of myocardial infarction or ischemic cerebrovascular accident

• Patient with end stage renal disease

• Patients with DNR status

• Incarcerated individuals